west china medical publishers
Keyword
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Keyword "慢性阻塞性肺疾病" 467 results
  • Effects of Smoking on Vibration Response Imaging

    Objective To explore the characteristics of vibration response imaging ( VRI) among heavy smokers whose pulmonary function is normal. Methods 67 heavy smokers with normal pulmonary function, 60 healthy non-smokers, and 60 patients with COPD were recruited. History taking, physical examination, lung function test, chest X-ray, and VRI examination were performed. The difference of VRI dynamic imaging between the three groups was analyzed. Results VRI vibration energy curve which appeared low, flat, sunken-in, and single peak accounted for 43.3% , 16.4% , 16.4% , and 14.9% respectively in the heavy smokers, accounted for 6.7% , 3.3% ,0% , and 0% respectively in the healthy nonsmokers, accounted for 60% , 33.3% , 18.3% , and 16.7% respectively in the COPD patients. The results between the heavy smokers and the healthy non-smokers were significantly different. Compared with the heavy smokers, the COPD patients exhibited more low and flat in expiration period. The energy peak value ratio of inspiration and expiration phase in the heavy smokers, the healthy non-smokers, and the COPD patients were 0.56,0.74, and 0.54 respectively. There was no significant difference between the heavy smokers and the COPD patients in peak value ratio of inspiration and expiration phase. Conclusion The vibration energy curve of the VRI in heavy smokers with normal pulmonary function is significantly different fromhealthy nonsmokers, but there is no significant difference between heavy smokers and COPD patients.

    Release date:2016-08-30 11:56 Export PDF Favorites Scan
  • Predictive value of inspiratory capacity and total lung capacity on acute exacerbation of chronic obstructive pulmonary disease

    Objective To study the predictive value of inspiratory capacity (IC) and total lung capacity (TLC) on acute exacerbation of patients with chronic obstructive pulmonary disease (COPD). Methods The in-patients due to acute exacerbation of COPD (AECOPD) from February 2017 to March 2019 were recruited in the study. Research data were collected during the recovery period and one year follow-up , and the patients were divided into two groups according to whether there was another acute exacerbation. Results A total of 372 patients were included in the study. In the patients with acute exacerbation, the age and TLC as a percentage of the expected value (TLC%pred) were higher, while IC as a percentage of the expected value (IC%pred) and the ratio of IC and TLC (IC/TLC) were lower. Univariate analysis revealed that IC/TLC≤25% was a significant predictor of acute exacerbation (P<0.001) after the AECOPD patients were discharged. Multivariable analysis revealed age (OR=1.25, 95%CI 1.17 to 1.44, P<0.001) and IC/TLC≤25% (OR=1.68, 95%CI 1.36 to 2.07, P<0.001) were independent risk factors of AECOPD.Conclusions Decreased IC/TLC significantly correlates with poor prognosis of COPD. IC/TLC≤25% is an independent risk factor for acute exacerbation.

    Release date:2022-01-12 11:04 Export PDF Favorites Scan
  • The significance of serum sRAGE combined with lung function and lung HRCT in predicting risk of COPD with NSCLC

    Objective To observe the value of serum soluble receptor of advanced glycation endproducts (sRAGE) combined with lung function and high resolution lung CT (HRCT) in predicting the risk of chronic obstructive pulmonary disease (COPD) developing non-small cell lung cancer (NSCLC). Methods From January 2019 to June 2021, 140 patients with COPD combined with NSCLC, 137 patients with COPD, and 133 patients with NSCLC were enrolled in the study from the People's Hospital of Ningxia Hui Autonomous Region. General data, clinical symptoms, pulmonary function indexes and HRCT emphysema indexes (EI) were collected. Serum sRAGE levels of these patients were measured by enzyme linked immunosorbent assay. Clinical characteristics of patients with COPD complicated with NSCLC were analyzed. Serum sRAGE, lung function and lung HRCT were combined to evaluate the correlation between the degree of emphysema and the occurrence of NSCLC in COPD, and receiver operator characteristic (ROC) curve analysis was performed for diagnostic efficiency. Results Compared with NSCLC group, COPD combined with NSCLC group had higher proportion of male patients, higher proportion of elderly patients, higher smoking index, and higher proportion of squamous cell carcinoma (P<0.05). FEV1 and FEV1%pred in COPD combined with NSCLC group were significantly lower than those in COPD group and NSCLC group. The Goddard score and EI values of emphysema were significantly increased (P<0.05). Serum sRAGE was significantly lower than that of COPD group and NSCLC group (P<0.05). Serum sRAGE level was positively correlated with FEV1%pred (r=0.366, P<0.001) and FEV1/FVC (r=0.419, P<0.001), and negatively correlated with Goddard score (r=–0.710, P=0.001) and EI value (r=–0.515, P<0.001). Binary multi-factor logistic regression analysis showed that age, smoking index, EI, Goddard score, RV/TLC were positively correlated with the risk of COPD developing NSCLC, while FEV1%pred, FVC, FEV1/FVC and serum sRAGE were negatively correlated with the risk of COPD developing NSCLC. ROC curve results showed that the area under the curve (AUC) of single diagnosis of sRAGE was 0.990, and the optimal cut-off value of 391.98 pg/mL with sensitivity of 93.3% and specificity of 89.7%. The AUC of sRAGE combined with age, smoking index, EI, Goddard score, FEV1%pred, FVC, FEV1/FVC, RV/TLC was 1.000 with sensitivity of 96.7%, specificity of 96.6%, and Yoden index of 0.933. Conclusion The combination of serum sRAGE, lung function and HRCT emphysema score can improve prediction of NSCLC occurrence in COPD.

    Release date:2023-10-18 09:49 Export PDF Favorites Scan
  • 沙美特罗/丙酸氟替卡松治疗慢性阻塞性肺疾病

    目的 观察沙美特罗/丙酸氟替卡松(舒利迭)治疗慢性阻塞性肺疾病的疗效。 方法 2005年6月-2008年10月慢性阻塞性肺疾病患者160例,随机分成治疗组和对照组各80例,两组均给予慢性阻塞性肺疾病常规抗感染、祛痰和解痉治疗,治疗组在此基础上给予沙美特罗/丙酸氟替卡松。 结果 治疗组治疗前后临床症状积分和肺功能有统计学意义(Plt;0.05),且未发现有任何毒副作用,对照组治疗前后无统计学意义(Pgt;0.05)。治疗后治疗组临床症状积分和肺功能明显优于对照组(Plt;0.05)。 结论 沙美特罗/丙酸氟替卡松能明显改善慢性阻塞性肺疾病患者的临床症状和肺功能。

    Release date:2016-09-08 09:47 Export PDF Favorites Scan
  • Changes of Airway Resistances before and after Bronchial Dilation Test in COPD and Asthma

    Objective To explore the profile and diagnosis value of airway resistances before and after bronchial dilation test ( BDT) in patients with COPD and asthma. Methods Airway resistances before and after BDT were measured in COPD patients and asthma patients with different severity by impulse oscillometry ( IOS) , and the characteristic changes of the two different diseases were analyzed compared with healthy subjects. Results Airway resistance indexes except X5 were higher in the COPD and the asthma patients than those in the healthy subjects before BDT ( P lt; 0. 05) . There were significant differences in airway resistance indexes except X5 and Rc between the mild asthma patients and the moderate to severe asthma patients. Significant difference in Z5, Fres, and Rp were observed in the mild COPD patientscompared with the moderate to severe COPD patients. There were statistical differences in airway resistance indexes except X5 between the two groups before and after BDT both in the COPD and the asthma patients ( P lt;0. 05) . The rates of change in Z5, Fres, R5, and Rp were higher than those of FEV1% pred, especially higher in the asthma patients than in the COPD patients ( P lt; 0. 05) . Significant negative correlations between FEV1% pred and Z5, Fres, R5, Rp were revealed in the COPD and the asthma patients ( P lt;0. 01) .The correlation between Fres and FEV1% pred was most significant in the COPD and the asthma patients ( r = - 0. 561, - 0. 761) . Conclusion Airway resistances measured by IOS is sensitive indicators in detecting the airflow obstruction in COPD and asthma, and is useful in early and differential diagnosis of COPD and asthma.

    Release date:2016-08-30 11:53 Export PDF Favorites Scan
  • 吸入剂治疗在慢性阻塞性肺疾病稳定期患者中的应用现状

    Release date:2016-09-13 04:07 Export PDF Favorites Scan
  • Efficacy of Non-invasive Bi-level Positive Airway Pressure Ventilation in the Patients with Type Ⅱ Respiratory Failure due to Acute Exacerbation of Chronic Obstructive Pulmonary Disease

    目的:评价经口鼻面罩双水平气道正压通气(BiPAP)治疗慢性阻塞性肺疾病急性加重期(AECOPD)并发Ⅱ型呼吸衰竭的临床疗效。〖HTH〗方法〖HTSS〗:对照组30例AECOPD并Ⅱ型呼吸衰竭患者给予吸氧、抗感染、化痰平喘等常规治疗,观察组38例AECOPD并Ⅱ型呼吸衰竭患者,在常规治疗的基础上同时进行BiPAP通气治疗。观察两组治疗前及治疗后4 h、24 h及72 h动脉血气变化,比较治疗前后呼吸频率、心率和白细胞计数以及血浆内皮素-1含量的变化,观察两组住院时间、气管插管率及病死率的变化。结果:观察组治疗后4 h、24 h及72 h动脉血气pH、PaO2、SaO2、PaO2/FiO2均明显高于对照组(Plt;0.05),PaCO2明显下降(Plt;0.05)。呼吸频率、心率和白细胞计数较对照组均下降(Plt;0.05)。观察组血浆内皮素-1含量恢复至正常水平快于对照组,观察组和对照组患者住院时间、气管插管率及病死率均有显著性差异(Plt;0.05)。〖HTH〗结论〖HTSS〗:BiPAP治疗慢性阻塞性肺疾病急性加重期并发Ⅱ型呼吸衰竭患者疗效确切,能减少住院时间、降低插管率和病死率。

    Release date:2016-09-08 09:56 Export PDF Favorites Scan
  • Effects of Smoking on SerumLeptin,Adiponectin, IL-6, and C-Reactive Protein in Rats

    Objective To investigate the role of inflammatory factors like serumleptin, adiponectin,interleukin-6( IL-6) , and C-reactive protein ( CRP) in the systemic inflammatory response of smokinginduced COPD. Methods Thirty male Wistar rats were randomly divided into three groups, ie. a high-dose smoking group, a low-dose smoking group, and a control group. Serum leptin, adiponectin, IL-6, and CRP levels were measured by ABC-ELISA. Results The serum leptin and adiponectin levels in both smoking groups decreased significantly compared with the control group( P lt; 0. 05) , while the difference was not significant between the two smoking groups ( P gt; 0. 05) . The serum IL-6 and CRP levels in both smoking groups increased significantly compared with the control group( P lt; 0. 05) , which were higher in the highdosesmoking group than those in the low-dose smoking group( P lt;0. 05) . Conclusions Smoking increases the serum levels of IL-6 and CRP, but reduces the serum levels of leptin and adiponectin in rats. These results suggest that leptin, adiponectin, IL-6, and CRP may be involved in the systemic inflammatory response of smoking-induced COPD.

    Release date:2016-08-30 11:53 Export PDF Favorites Scan
  • Enlightenment of TORCH Study and Its Follow-up Analysis on Clinical Practice

    慢性阻塞性肺疾病( COPD) 在全球的患病率和死亡率均高居不下, 并有不断增长的趋势, 由此带来了沉重的经济和社会负担。2011 年《COPD 诊断、管理和预防的全球策略》( 以下简称“GOLD 策略”) 更新内容中, 将COPD 定义为一种可防可治的常见疾病, 以持续性气流受限为特征[ 1] 。气流受限呈进行性发展, 伴有气道和肺对有害颗粒或气体所致慢性炎症反应的增加。急性加重和合并症影响患者整体疾病的严重程度。此外, 2011 版GOLD 策略还更新了疾病评价标准, 不再简单地根据气流受限分级治疗, 而是提出整合了患者临床症状、气流受限程度以及急性加重风险等三方面综合评估的概念[ 1 ] 。同时指出, 对于高风险患者, 无论临床症状多少, 吸入糖皮质激素 ( ICS) 与长效β2 受体激动剂( LABA) 联合治疗是 GOLD 策略推荐的首选治疗方案之一。支持这一建议的一个重要或里程碑式的循证医学证据就是“迈向COPD 患者健康的变革 ( TORCH) ”的研究[ 2 ] 。该研究从研究设计、研究主要结果、研究结果的亚组分析及影响因素等多方面进行了详细的分析, 并相继在众多国际著名医学杂志发表了16 篇文章[ 2-1 7] , 成绩斐然, 对COPD 防治策略的制订产生了非常积极的影响。认真分析和借鉴TORCH 研究及其后续分析带给我们的启示, 对提升今后疾病的临床研究质量、发掘研究成果、促进 COPD 的防治等方面将有积极的意义。

    Release date: Export PDF Favorites Scan
  • Serum Level of Surfactant Protein D in Patients with Chronic Obstructive Pulmonary Disease

    Objective To investigate the serum level of surfactant protein D ( SP-D) in patients with chronic obstructive pulmonary disease ( COPD) and its clinical significance. Methods Serumlevels of SP-D in patients with acute exacerbations of COPD ( n = 29) , stable COPD ( n = 26) , and control subjects ( n = 19 ) were measured by ELISA. Multiple regression modeling was performed to determine the independent relationship between SP-D and lung function variables. Results The serum SP-D levels were significantly increased in the patients who experienced an acute exacerbation [ ( 70. 6 ±20. 7) ng/mL] compared with the patients with stable COPD and the control subjects [ ( 47. 9 ±13. 3) ng/mL and ( 31. 2 ±11. 4) ng/mL] ( both P lt; 0. 01) . The serum SP-D levels in the patients with stable COPD increased significantly than the control subjects ( P lt; 0. 01) . Smoking index and staging of COPD were positively related to SP-D level. Serum SP-D levels were also found to be inversely related to FEV1% pred in stable COPD. Conclusion Serum SP-D may be a potential diagnostic and staging biomarker for COPD.

    Release date:2016-08-30 11:56 Export PDF Favorites Scan
47 pages Previous 1 2 3 ... 47 Next

Format

Content